Prostate Specific Antigen/AACT Complex Antibody (2F5): sc-53143

PSA/ACT Antibody (2F5) is a mouse monoclonal IgG1 antibody that detects prostate specific antigen (PSA) in human samples through applications such as western blotting (WB) and immunofluorescence (IF). PSA, also known as gamma-seminoprotein, seminin, p30 antigen, semenogelase, and kallikrein 3 (KLK3), is a serine protease primarily produced in the prostate gland, where PSA plays a crucial role in the liquefaction of semen by hydrolyzing semenogelin I, a major protein in seminal plasma. This enzymatic activity is vital for male fertility, as PSA allows sperm to swim freely after ejaculation. Elevated levels of PSA in the blood are often associated with prostate cancer, making PSA an important biomarker for early detection and monitoring of the disease. In addition to PSA presence in prostate tissues, PSA has also been found in accessory male sex glands and breast cancer tissues, highlighting PSA potential relevance in various malignancies. Anti-PSA/ACT antibody (2F5) is an essential tool for researchers studying prostate cancer and associated pathways, providing reliable detection and analysis of PSA in various experimental settings.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Prostate Specific Antigen/AACT Complex Antibody (2F5) References:

1. Different molecular forms of uncomplexed prostate specific antigen (PSA) show similar immunoreactivities.  |  Chu, LF., et al. 1999. J Urol. 161: 2009-12. PMID: 10332491
2. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells.  |  Yeung, F., et al. 2000. J Biol Chem. 275: 40846-55. PMID: 11006269
3. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.  |  Peracaula, R., et al. 2003. Glycobiology. 13: 457-70. PMID: 12626390
4. Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex.  |  Wan, XS., et al. 2003. Prostate. 56: 131-41. PMID: 12746838
5. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase.  |  Kristal, AR., et al. 2006. Cancer. 106: 320-8. PMID: 16342294
6. Glycan analysis of Prostate Specific Antigen (PSA) directly from the intact glycoprotein by HR-ESI/TOF-MS.  |  Behnken, HN., et al. 2014. J Proteome Res. 13: 997-1001. PMID: 24393138
7. Portable smartphone quantitation of prostate specific antigen (PSA) in a fluoropolymer microfluidic device.  |  Barbosa, AI., et al. 2015. Biosens Bioelectron. 70: 5-14. PMID: 25775968
8. Significance of measurement of prostate specific antigen (PSA) in familial prostate cancer lines.  |  Ohtake, N., et al. 1998. Tohoku J Exp Med. 184: 21-8. PMID: 9607395
9. Monoclonal antibodies 2F5 and 4G10 against prostate specific antigen (PSA) complexed to alpha1-antichymotrypsin.  |  Chen, Z., et al. 1998. J Urol. 160: 870-5. PMID: 9720579
10. The value of prostate specific antigen (PSA) density and free: total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation.  |  Klingler, HC., et al. 1998. Br J Urol. 82: 393-7. PMID: 9772877

The preferred PSA/KLK3/Kallikrein 3/Prostate Specific Antigen antibody is PSA/KLK3/Kallikrein 3/Prostate Specific Antigen Antibody (A67-B/E3): sc-7316.